Skip to main content
SpringerLink
Log in

Valproate hepatotoxicity syndrome: Hypotheses of pathogenesis

  • Published:
Pharmaceutisch Weekblad Aims and scope Submit manuscript

Abstract

Therapeutic use of the anticonvulsant valproate (VPA) has been associated with a rare, but severe and often fatal hepatotoxicity. Cases usually present with lethargy, anorexia, and vomiting with rapid progression to coma. Liver histopathology is characterized by steatosis with and without necrosis. In some instances only necrosis was present. Several hypotheses of pathogenesis have been postulated. These deal mainly with biochemical systems that are known to be affected by VPA, or with the possible idiosyncratic production of toxic VPA metabolites, especially Δ4-VPA. At present, no hypothesis entirely explains the diverse characteristics of the disorder.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gerber N, Dickinson RG, Harlan RC, Lynn RK, Houghton D, Antonias JI, et al. Reye-like syndrome associated with valproic acid therapy. J Pediatr 1979;95:142–4.

    PubMed  Google Scholar 

  2. Suchy FJ, Balistreri WF, Buchino JJ, Sondheimer JM, Bates SR, Kearns GL, et al. Acute hepatic failure associated with the use of sodium valproate. N Engl J Med 1979;300:962–6.

    PubMed  Google Scholar 

  3. Zimmerman H, Ishak HJ. Valproate-induced hepatic injury: analysis of 23 fatal cases. Hepatology 1982;2:591–7.

    PubMed  Google Scholar 

  4. Zafrani ES, Berthelot P. Sodium valproate in the induction of unusual hepatotoxicity. Hepatology 1982;2:648–9.

    PubMed  Google Scholar 

  5. Willmore LJ, Wilder B J, Bruni J, Villarreal HJ. Effect of valproic acid on hepatic function. Neurology 1978; 28:961–4.

    PubMed  Google Scholar 

  6. Sussman NM, McLain LW. A direct hepatotoxic effect of valproic acid. JAMA 1979;242:1173–4.

    Article  PubMed  Google Scholar 

  7. Jeavons PM. Non-dose-related side effects of valproate. Epilepsia 1984;25 Suppl 1:S50–5.

    PubMed  Google Scholar 

  8. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987;37:379–85.

    PubMed  Google Scholar 

  9. Sheffner D. Fatal liver failure in children on valproate. Lancet 1986;2:511.

    Article  Google Scholar 

  10. Dickinson RG, Bassett ML, Searle J, Tyrer JH, Eadie MJ. Valproate hepatotoxicity: a review and report of two instances in adults. Clin Exp Neurol 1985;21:79–91.

    PubMed  Google Scholar 

  11. Gram L. Hepatic toxicity of valproate: reflection on the pathogenesis and proposal for an international collaborative registration. In: Oxley J, Janz D, Meinardi H, eds. Chronic toxicity of antiepileptic drugs. New York: Raven Press, 1983:67–78.

    Google Scholar 

  12. Eadie MJ, Hooper WD, Dickinson RG. Valproateassociated hepatotoxicity and its biochemical mechanisms. Med Toxicol 1988;3:85–106.

    Google Scholar 

  13. Coulter DL, Allen RJ. Secondary hyperammonemia: a possible mechanism for valproate encephalopathy. Lancet 1980;1:1310–1.

    Article  PubMed  Google Scholar 

  14. Lewis JH, Zimmerman HJ, Garrett CT, Rosenberg E. Valproate-induced hepatic steatogenesis in rats. Hepatology 1982;2:870–3.

    PubMed  Google Scholar 

  15. Kesterson JW, Granneman GR, Machinist JM. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology 1984;4:1143–52.

    Google Scholar 

  16. Sugimoto T, Araki A, Nishida N, Sakane Y, Woo M, Takeuchi T, et al. Hepatotoxicity in rat following administration of valproic acid: effect of L-carnitine supplementation. Epilepsia 1987;28:373–7.

    PubMed  Google Scholar 

  17. Becker C-M, Harris RA. Influence of valproic acid on hepatic carbohydrate and lipid metabolism. Arch Biochem Biophys 1983;223:381–92.

    Article  PubMed  Google Scholar 

  18. Bjorge SM, Baillie TA. Inhibition of medium-chain fatty acidβ-oxidationin vitro by valproic acid and its unsaturated metabolite, 2-n-propyl-4-pentenoic acid. Biochem Biophys Res Commun 1985;132:245–52.

    Article  PubMed  Google Scholar 

  19. Coude FX, Grimber G, Pelet A, Benoit Y. Action of the antiepileptic drug, valproic acid, on fatty acid oxidation in isolated rat hepatocytes. Biochem Biophys Res Commun 1983;115:730–6.

    Article  PubMed  Google Scholar 

  20. Turnbull DM, Dick DJ, Wilson L, Sherratt HSA, Alberti KGMM. Valproate causes metabolic disturbances in normal man. J Neurol Neurosurg Psychiatr 1986;49:405–10.

    PubMed  Google Scholar 

  21. Moore KH, Decker BP, Schreefel FP. Hepatic hydrolysis of octanoyl-CoA and valproyl-CoA in control and valproate-treated animals. Int J Biochem 1988;20:175–8.

    Article  PubMed  Google Scholar 

  22. Stumpf DA, Parker D, Angelini C. Carnitine deficiency, organic acidemias, and Reye's syndrome. Neurology 1985;35:1041–5.

    PubMed  Google Scholar 

  23. Bohles H, Richter K, Wagne-Thiessen E, Schafer H. Decreased serum carnitine in valproate induced Reye syndrome. Eur J Pediatr 1982;139:185–6.

    Article  PubMed  Google Scholar 

  24. Coulter DL. Carnitine deficiency: a possible mechanism for valproate hepatotoxicity. Lancet 1984;1:689.

    Article  Google Scholar 

  25. Ohtani Y, Endo F, Matsuda I. Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J Pediatr 1982;101:782–5.

    PubMed  Google Scholar 

  26. Laub MC, Paltzke-Brunner I, Jaeger G. Serum carnitine during valproic acid therapy. Epilepsia 1986;27:559–62.

    PubMed  Google Scholar 

  27. Murphy JV, Marquardt KM, Shug AL. Valproic acid associated abnormalities of carnitine metabolism. Lancet 1985;1:820–1.

    Article  Google Scholar 

  28. Beghi E, Bizzi A, Codegoni AM, Trevisan D, Torri W, Collaborative Group for the Study of Epilepsy. Valproate, carnitine metabolism and biochemical indicators of liver function. Epilepsia 1990;31(3):346–52.

    PubMed  Google Scholar 

  29. Melegh B, Kerner J, Acsadi G, Lakatos J, Sandor A.l-Carnitine replacement therapy in chronic valproate treatment. Neuropediatrics 1990;21:40–3.

    PubMed  Google Scholar 

  30. Melegh B, Kerner J, Kispal G, Acsadi G, Dani M. Effect of chronic valproic acid treatment on plasma and urine carnitine levels in children: decreased urinary excretion. Acta Paed Hungar 1987;28(2):137–42.

    Google Scholar 

  31. Coulter DL, Allen RJ. Hyperammonemia with valproic acid therapy. J Pediatr 1981;99:317–9.

    PubMed  Google Scholar 

  32. Laub MC. Nutritional influence of serum ammonia in young patients receiving sodium valproate. Epilepsia 1986;27:55–9.

    PubMed  Google Scholar 

  33. Rawat S, Borkowski WJ, Swick HM. Valproic acid and secondary hyperammonemia. Neurology 1981;31:1173–4.

    PubMed  Google Scholar 

  34. Williams CA, Tiefenback S, McReynolds JW. Valproic acid-induced hyperammonemia in mentally retarded adults. Neurology 1984;34:550–3.

    PubMed  Google Scholar 

  35. Zaccara G, Campostrini R, Paganini M, Moroni F, Valenza T, Targioni G, et al. Acute changes of blood ammonia may predict short-term adverse effects of valproic acid. Neurology 1984;34:1519–21.

    PubMed  Google Scholar 

  36. Zaccara G, Paganini M, Campostrini R, Moroni F, Valenza T, Messori A, et al. Effect of associated antiepileptic treatment on valproate-induced hyperammonemia. Ther Drug Monitor 1985;7:185–90.

    Google Scholar 

  37. Ratnaike RN, Schapel GJ, Purdie G, Rischbieth RHC, Hoffman S. Hyperammonemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs. Br J Clin Pharmacol 1986;22:100–3.

    PubMed  Google Scholar 

  38. Warter JM, Brandt C, Marescaux C, Rumbach L, Micheletti G, Chabrier G, et al. The renal origin of sodium valproate-induced hyperammonemia in fasting humans. Neurology 1983;33:1136–40.

    PubMed  Google Scholar 

  39. Warter J, Imler M, Marescaux C, Chabrier G, Rumbach L, Micheletti G, et al. Sodium valproateinduced hyperammonemia in the rat: role of the kidney. Eur J Pharmacol 1983;87:177–82.

    Article  PubMed  Google Scholar 

  40. Hjelm M, De Silva LVK, Seakins JWT, Oberholzer VG, Rolles C J. Evidence of inherited urea cycle defect in a case of fatal valproate toxicity. BMJ 1986;292: 23–4.

    PubMed  Google Scholar 

  41. Tripp JH, Hargreaves T, Anthony PP, Searle JF, Miller P, Leonard JV, et al. Sodium valproate and ornithine carboxyl transferase deficiency. Lancet 1981;1: 1165–6.

    Article  Google Scholar 

  42. Sherratt HSA, Osmundsen H. On the mechanisms of some pharmacological actions of the hypoglycemic toxins hypoglycin and pent-4-enoic acid: a way out of the confusion. Biochem Pharmacol 1976;25:743–50.

    Article  PubMed  Google Scholar 

  43. Baillie TA. Metabolism of valproate to hepatotoxic intermediates. Pharm Weekbl [Sci] 1992;14(3A):122–5.

    Google Scholar 

  44. Levy RH, Lin JMH, Acheampong AA, Russell RG. Dose effect of L-carnitine on Δ4-VPA associated hepatotoxicity. In: Levy RH, Penry JK, eds. Idiosyncratic reactions to valproate: clinical risk patterns and mechanisms of toxicity. New York: Raven Press, 1991: 25–9.

    Google Scholar 

  45. Levy RH, Rettenmeier AW, Anderson GD, Wilensky AJ, Friel PN, Baillie TA, et al. Effects of polytherapy with phenytoin, carbamazepine, and stiripentol of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther 1990;48:225–35.

    PubMed  Google Scholar 

  46. Farrell K, Abbott FS, Junker AK, Waddell JS, Pippenger CE. Successful treatment of valproate hepatotoxicity withN-acetylcysteine. Epilepsia 1989;30(5):700.

    Google Scholar 

  47. Appleton RE, Farrell K, Applegrath DA, Dimmick JE, Wong LTK, Davidson AGF. The high incidence of valproate hepatotoxicity in infants may relate to familial metabolic defects. Can J Neurol Sci 1990;17:145–8.

    PubMed  Google Scholar 

  48. Lenn NJ, Ellis WG, Washburn ER, Ruebner B. Fatal hepatocerebral syndrome in siblings discordant for exposure to valproate. Epilepsia 1990;31(5):578–93.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutics, School of Pharmacy, BG-20, University of Washington, 98195, Seattle, Washington, USA

    Jeffrey R. Stephens & René H. Levy

Authors
  1. Jeffrey R. Stephens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. René H. Levy
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stephens, J.R., Levy, R.H. Valproate hepatotoxicity syndrome: Hypotheses of pathogenesis. Pharmaceutisch Weekblad Scientific Edition 14, 118–121 (1992). https://doi.org/10.1007/BF01962700

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01962700

Keywords

Search

Navigation